293 related articles for article (PubMed ID: 26843405)
1. Immunotherapy for pancreatic cancer.
Kotteas E; Saif MW; Syrigos K
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1795-805. PubMed ID: 26843405
[TBL] [Abstract][Full Text] [Related]
2. Immune Therapy in Pancreatic Cancer: Now and the Future?
Zhang Y; Choi M
Rev Recent Clin Trials; 2015; 10(4):317-25. PubMed ID: 26374557
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy updates in pancreatic cancer: are we there yet?
Gunturu KS; Rossi GR; Saif MW
Ther Adv Med Oncol; 2013 Jan; 5(1):81-9. PubMed ID: 23323149
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.
Garrido-Laguna I; Hidalgo M
Nat Rev Clin Oncol; 2015 Jun; 12(6):319-34. PubMed ID: 25824606
[TBL] [Abstract][Full Text] [Related]
6. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
7. Selecting chemotherapy for pancreatic cancer: Far away or so close?
Shi S; Yu X
Semin Oncol; 2019 Feb; 46(1):39-47. PubMed ID: 30611527
[TBL] [Abstract][Full Text] [Related]
8. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
9. New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy.
Lowery MA; O'Reilly EM
BioDrugs; 2011 Aug; 25(4):207-16. PubMed ID: 21815696
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
11. Current and future immunotherapeutic approaches in pancreatic cancer treatment.
Farhangnia P; Khorramdelazad H; Nickho H; Delbandi AA
J Hematol Oncol; 2024 Jun; 17(1):40. PubMed ID: 38835055
[TBL] [Abstract][Full Text] [Related]
12. What is recent in pancreatic cancer immunotherapy?
Niccolai E; Prisco D; D'Elios MM; Amedei A
Biomed Res Int; 2013; 2013():492372. PubMed ID: 23509731
[TBL] [Abstract][Full Text] [Related]
13. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
15. New Approaches for Immune Directed Treatment for Ovarian Cancer.
Hardwick N; Frankel PH; Cristea M
Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589
[TBL] [Abstract][Full Text] [Related]
16. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatment of pancreatic cancer revisited.
Ducreux M; Seufferlein T; Van Laethem JL; Laurent-Puig P; Smolenschi C; Malka D; Boige V; Hollebecque A; Conroy T
Semin Oncol; 2019 Feb; 46(1):28-38. PubMed ID: 30638624
[TBL] [Abstract][Full Text] [Related]
18. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
Hopkins AC; Yarchoan M; Durham JN; Yusko EC; Rytlewski JA; Robins HS; Laheru DA; Le DT; Lutz ER; Jaffee EM
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997287
[TBL] [Abstract][Full Text] [Related]
19. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Santucci J; Tacey M; Thomson B; Michael M; Wong R; Shapiro J; Jennens R; Clarke K; Pattison S; Burge M; Zielinski R; Nikfarjam M; Ananda S; Lipton L; Gibbs P; Lee B
Eur J Cancer; 2022 Oct; 174():102-112. PubMed ID: 35988408
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies.
Matsui H; Hazama S; Shindo Y; Nagano H
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1205-1217. PubMed ID: 30295097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]